Targeted toxins

Clinical Cancer Research

Volumn 6, Issue 2, 2000, Pages 326-334

  Frankel, Arthur E ^a   Kreitman, Robert J ^b   Sausville, Edward A ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOTOXIN; POLYPEPTIDE; PROTEIN SYNTHESIS INHIBITOR;

APOPTOSIS; CANCER CELL; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; META ANALYSIS; NAUSEA; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; SHORT SURVEY;

ANTINEOPLASTIC AGENTS; CYTOTOXINS; DRUG DESIGN; HUMANS; IMMUNOTOXINS; NEOPLASMS;

EID: 0033964059     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (59)

1. Pai, J. H., Wittes, R., Setser, A., Willingham, M. C., and Pastan, I. Treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to Pseudomonas exotoxin. Nat. Med., 2: 350, 1996.
2. Haggerty, H. G., Warner, W. A., Comereski, C. R., Peden, W. M., Mezza, L. E., Damle, B. D., Siegall, C. B., and Davidson, T. J. BR96-sFv-PE40 immunotoxin: nonclinical safety assessment. Toxicol. Pathol., 27: 87, 1999.
3. Benhar, I., Reiter, Y., Pai, L. H., and Pastan, I. Administration of disulfide-stabilized Fv-immunotoxins B1(dsFv)-PE38 and B3(dsFv)-PE38 by continuous infusion increases their efficacy in curing large tumor xenografts in nude mice. Int. J. Cancer, 62: 351-355, 1995.
4. Amlot, P. L., Stone, M. J., Cunningham, D., Fay, J., Newman, J., Collins, R., May, R., McCarthy, M., Richardson, J., Ghetie, V., Ramilo, O., Thorpe, P. E., Uhr, J. W., and Vitetta, E. S. A Phase I study of an anti-CD22-deglcysylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood, 82: 2624-2633, 1993.
5. Vitetta, E. S., Stone, M., Amlot, P., Fay, J., May, R., Till, M., Newman, J., Clark, P., Collins, R., Cunningham, D., Ghetie, V., Uhr, J. W., and Thorpe, P. E. Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res., 51: 4052-4058, 1991.
6. Kreitman, R. J., Wilson, W. H., Margulies, I., Stetler-Stevenson, M., Raggio, M., FitzGerald, D. J., Waldmann, T. A., and Pastan, I. Patients with chemotherapy-refractory hairy cell leukemia achieve major responses to recombinant immunotoxins containing truncated Pseudomonas exotoxin and targeting either CD25 or CD22. Blood, in press, 2000.
7. Stone, M. J., Sausville, E. A., Fay, J. W., Headlee, D., Collins, R. H., Figg, W. D., Stetler-Stevenson, M., Jain, V., Jaffe, E. S., Solomon, D., Lush, R. M., Senderowicz, A., Ghetie, V., Schindler, J., Uhr, J. W., and Vitetta, E. S. A Phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma. Blood, 88: 1188-1197, 1996.
8. Uckun, F. Immunotoxin for the treatment of leukaemia. Br. J. Haematol., 85: 435-438, 1993.
9. Grossbard, M. L., Lambert, J. M., Goldmacher, V. S., Spector, N. L., Kinsella, J., Eliseo, L., Coral, F., Taylor, J. A., Blattler, W. A., Epstein, C. L., and Nadler, J. M. Anti-B4-blocked ricin: a Phase I trial of 7-day continuous infusion in patients with B-cell neoplasms. J. Clin. Oncol., 11: 726-737, 1993.
10. Waldman, T., Pastan, I., Gansow, O., and Junghans, R. The multichain interleukin-2 receptor: a target for immunotherapy. Ann. Intern. Med., 116: 148-160, 1992.
11. Schnell, R., Vitetta, E. S., Schindler, J., Barth, S., Winkler, U., Borchmann, P., Hansmann, M. L., Diehl, V., Ghetie, V., and Engert, A. Clinical trials with an anti-CD25 ricin A-chain experimental and immunotoxin (RFT5-SMPT-dgA) in Hodgkin's lymphoma. Leuk. Lymphoma, 30: 525-537, 1998.
12. Kreitman, R. J., Wilson, W. H., Robbins, D., Marguiles, I., Stetler-Stevenson, M., Waldmann, T. A., and Pastan, I. Responses in refractory hairy cell leukemia to a recombinant immunotoxin. Blood, in press, 2000.
13. Laske, D. W., Youle, R., and Oldfield, E. H. Tumor regression with regional distribution of the targeted toxin Tf-CRM107 in patients with malignant brain tumors. Nat. Med., 3: 1362-1368, 1997.
14. Laske, D. W., Muraszko, K. M., Oldfield, E. H., DeVroom, H. L., Sung, C., Dedrick, R. L., Simon, T. R., Colandrea, J., Copeland, C., Katz, D., Greenfield, L., Groves, E. S., Houston, L. L., and Youle, R. J. Intraventricular immunotoxin therapy for leptomeningeal neoplasia. Neurosurgery, 41: 1039-1049, 1997.
15. Husain, S. R., Behari, N., Kreitman, R. J., Pastan, I., and Puri, R. K. Complete regression of established human glioblastoma tumor xenografts by interleukin-4 toxin therapy. Cancer Res., 58: 3649-3653, 1998.
16. Pagliaro, L. C., Liu, B., Munker, R., Andreef, M., Freireich, E. J., Scheinberg, D. A., and Rosenblum, M. G. Humanized M195 monoclonal antibody conjugated to recombinant gelonin: an anti-CD33 immunotoxin with antileukemic activity. Clin. Cancer Res., 4: 1971-1976, 1998.
17. Frankel, A. E., Hall, P. D., and Kreitman, R. J. Steroid prophylaxis prevents systemic inflammatory response syndrome (SIRS) in AML patients treated with diphtheria fusion protein. Blood, in press, 2000.
18. Lynch, T. J., Lambert, J. M., Coral, F., Shefner, J., Wen, P., Blattler, W. A., Collinson, A. R., Ariniello, P. D., Braman, G., Cook, S., Esseltine, D., Elias, A., Skarin, A., and Ritz, J. Immunotoxin therapy of small-cell lung cancer: a Phase I study of N901-blocked ricin. J. Clin. Oncol., 15: 723-734, 1997.
19. Goldberg, M. R., Heimbrook, D. C., Russo, P., Sarosdy, M. F., Greenberg, R. E., Giantonio, B. J., Linehan, W. M., Walther, M., Fisher, H. A. G., Messing, E., Crawford, E. D., Oliff, A. I., and Pastan, I. H. Phase I clinical study of the recombinant oncotoxin TP40 in superficial bladder cancer. Clin. Cancer Res, 1: 57, 1995.
20. 389EGF in patients with epidermal growth factor receptor (EGF-R) expressing solid tumors. Proceedings of the Fourth International Symposium on Immunotoxins, p. 138, Myrtle Beach, 1995.
21. Byers, V. S., Rodvien, R., Grant, K., Durrant, L. G., Hudson, K. H., Baldwin, R. W., and Scannon, P. J. Phase I study of monoclonal antibody-ricin A chain immunotoxin XomaZyme-791 in patients with metastatic colon cancer. Cancer Res., 49: 6153-6160, 1989.
22. Gould, B. J., Borowitz, M. J., Groves, E. S., Carter, P. W., Anthony, D., Weiner, L., and Frankel, A. E. Phase I study of an anti-breast cancer immunotoxin by continuous infusion: report of a targeted toxic effect not predicted by animal studies. J. Natl. Cancer Inst., 81: 775-781, 1989.
23. Falin, B., Bolognesi, A., Flenghi, L., Tazzari, P., Broe, M., Stein, H., Durkop, H., Aversa, F., Corneli, P., Pizzolo, G., Barbabietola, G., Sabattini, E., Pileri, S., Martelli, M., and Stirpe, F. Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin. Lancet, 339: 1195-1196, 1992.
24. Hertler, A., Schlossman, D., Borowitz, M., Blythman, H., Casellas, P., and Frankel, A. An anti-CD5 immunotoxin for chronic lymphocytic leukemia: enhancement of cytotoxicity with human serum albumin-monensin. Int. J. Cancer, 43: 215-219, 1989.
25. LeMaistre, C. F., Rosen, S., Frankel, A., Kornfeld, S., Saria, E., Meneghetti, C., Drajesk, J., Fishwild, D., Scannon, P., and Byers, V. Phase I trial of H65-RTA immunoconjugate in patients with cutaneous T-cell lymphoma. Blood, 78: 1173-1182, 1991.
26. Spitler, L. E., del Rio, M., Khentigan, A., Wedel, N. I., Brophy, N. A., Miller, L. I., Harkonen, W. S., Rosendorf, L. L., Lee, H. M., Mischak, R. P., Kawahata, R. T., Stoudemire, J. B., Fradkin, L. B., Bautista, E. E., and Scannon, P. J. Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibody-ricin A chain immunotoxin. Cancer Res., 47: 1717-1723, 1987.
27. Pai, L., Bookman, M., Ozols, R., Young, R., Smith, J., Longo, D., Gould, B., Frankel, A., McClay, E., Howell, S., Reed, E., Willingham, M. C., FitzGerald, D. J., and Pastan, I. Clinical evaluation of intraperitoneal Pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer. J. Clin. Oncol., 9: 2095-2103, 1991.
28. Frankel, A. E., Laver, J. H., Willingham, M. C., Burns, L. J., Kersey, J. H., and Vallera, D. A. Therapy of patients with T-cell lymphomas and leukemias using an anti-CD7 monoclonal antibody-ricin A chain immunotoxin. Leuk. Lymphoma, 26: 287-298, 1997.
29. Waurzyniak, B., Schneider, E. A., Tumer, N., Yanishevski, Y., Gunther, R., Chelstrom, L. M., Wendorf, H., Myers, D. E., Irvin, J. D., Messinger, Y., Ek, O., Zeren, T., Langlie, M. C., Evans, W. E., and Uckun, F. M. In vivo toxicity, pharmacokinetics, and antileukemic activity of TXU (anti-CD7)-pokeweed antiviral protein immunotoxin. Clin. Cancer Res., 3: 881-890, 1997.
30. Pai-Scherf, L. H., Villa, J., Pearson, D., Watson, T., Liu, E., Willingham, M. C., and Pastan, I. Hepatotoxicity in cancer patients receiving Erb-38, a recombinant immunotoxin that targets the erbB2 receptor. Clin. Cancer Res., in press, 2000.
31. Foss, F. M., Borkowski, T. A., Gilliom, M., Stetler-Stevenson, M. A., Jaffe, E. S., Figg, W. D., Tompkins, A., Bastian, A., Nylen, P., Woodworth, T., Udey, M. C., and Sausville, E. A. Chimeric fusion protein toxin DAB486IL-2 in advanced Mycosis fungoides and the Sezary syndrome: correlation of activity and interleukin-2 receptor expression in a phase II study. Blood, 84: 1765-1774.
32. Choe, S., Bennett, M., Fujii, G., Curmi, P., Kantardjieff, K., Collier, R., and Eisenberg, D. The crystal structure of diphtheria toxin. Nature (Lond.), 357: 216-222, 1992.
33. Greenfield, L., Johnson, V. G., and Youle, R. J. Mutations in diphtheria toxin separate binding from entry and amplify immunotoxin selectivity. Science (Washington DC), 238: 536-539, 1987.
34. 486IL-2). Fragment B sequences required for the delivery of fragment A to the cytosol of target cells. J. Biol. Chem., 265: 11885-11889, 1990.
35. Hwang, J., FitzGerald, D., Adhya, S., and Pastan. I. Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli. Cell, 48: 129-136, 1987.
36. Pastan, I., Pai, L. H., Brinkmann, U., and FitzGerald, D. J. Recombinant toxins: new therapeutic agents for cancer Ann. NY Acad. Sci., 758: 345-354, 1995.
37. Montfort, W., Villafranca, J., Monzingo, A., Ernst, S., Katzin, B., Rutenber, E., Xuong, N., Hamlin, R., and Robertus, J. The three-dimensional structure of ricin at 2.8 angstroms. J. Biol. Chem., 262: 5398-5403, 1987.
38. Jansen, F. K., Blythman, H. E., Carriere, D., Casellas. P., Gros, O., Gros, P., Eaurent, J. C., Paolucci, F., Pau, B., Poncelet, P., Richer, G., Vidal, H., and Voisin, G. A. Immunotoxins: hybrid molecules combining high specificity and potent cytotoxicity. Immunol. Rev., 62: 185-216, 1982.
39. Lambert, J. M., Goldmacher, V. S., Collinson, A. R., Nadler, L. M., and Blattler, W. A. An immunotoxin prepared with blocked ricin: a natural plant toxin adapted for therapeutic use. Cancer Res., 51: 6236-6242, 1991.
40. Irvin, J. D. Pokeweed antiviral protein. Pharmacol. Ther., 21: 371-387, 1983.
41. Baluna, R., Rizo, J., Gordon, B. E., Ghetie, V., and Vitetta, E. S. Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome. Proc. Natl. Acad. Sci. USA, 96: 3957-3962, 1999.
42. Sausville, E. A., Headlee, D., Stetler-Stevenson, M., Jaffe, E. S., Solomon, D., Figg, W. D., Herdt, J., Kopp, W. C., Rager, H., Steinberg, S. M., Ghetie, V., Schindler, J., Uhr, J., Wittes, R. E., and Vitetta, E. S. Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a Phase I study. Blood, 85: 3457-3465, 1995.
43. Senderowicz, A. M., Vitetta, E. S., Headlee, D., Ghetie, V., Uhr, J. W., Figg, W. D., Lush, R. M., Stetler-Stevenson, M., Kershaw, G., Kingma, D. W., Jaffe, E. S., and Sausville, E. A. Complete sustained response of a refractory, post-transplantation, large B-cell lymphoma to an anti-CD22 immunotoxin. Ann. Intern. Med., 126: 882-885, 1997.
44. Grossbard, M. L., Freedman, A. S., Ritz, J., Coral, F., Goldmacher, V. S., Eliseo, L., Spector, N., Dear, K., Lambert, J. M., Blattler, W. A., Taylor, J. A., and Nadler, L. M. Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a Phase I trial of daily bolus infusion. Blood, 79: 576, 1992.
45. Hesketh, P., Caguioa, P., Koh, H., Dewey, H., Facada, A., McCaffrey, R., Parker, K., Nylen, P., and Woodworm, T. Clinical activity of a cytotoxic fusion protein in the treatment of cutaneous T-cell lymphoma. J. Clin. Oncol., 11: 1682-1690, 1993.
46. Weiner, L. M., O'Dwyer, J. O., Kitson, J., Comis, R. L., Frankel, A. E., Bauer, R. J., Konrad, M. S., and Groves, E. S. Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9-recombinant ricin A chain immunoconjugate. Cancer Res., 49: 4062-4067, 1989.
47. Bookman, M. A. Biological therapy of ovarian cancer: current directions. Semin. Oncol., 25: 381-396, 1998.
48. Heestand, G., Robbin, D. H., Onda, M., Pastan, I., and Kreitman, R. J. Recombinant toxins containing Pseudomonas exotoxin directly injure hepatocytes in the absence of Kupffer cells. Blood, in press, 2000.
49. Schumann, J., Angermuller, S., Bang, R., Lohoff, M., and Tieggs, G. Acute hepatotoxicity of Pseudomonas aeruginosa exotoxin A in mice depends on T cells and TNF. J. Immunol., 161: 5745-5754, 1998.
50. Soler-Rodriguez, A., Ghetie, M., Oppenheimer-Marks, N., Uhr, J., and Vitetta, E. Ricin A-chain and ricin A-chain immunotoxins rapidly damage human endothelial cells: implications for vascular leak syndrome. Exp. Cell Res., 206: 227-234, 1993.
51. Siegall, C., Liggitt, D., Chace, D., Tepper, M., and Fell, H. Prevention of immunotoxin-mediated vascular leak syndrome in rats with retention of antitumor activity. Proc. Natl. Acad. Sci. USA, 91: 9514, 1994.
52. Rozemuller, H., Rombouts, W. J., Touw, I. P., FitzGerald, D. J., Kreitman, R. J., Pastan, I., Hagenbeek, A., and Martens, A. C. Treatment of acute myelocytic leukemia with interleukin-6 Pseudomonas exotoxin fusion protein in a rat leukemia model. Leukemia (Baltimore), 10: 1796-1803, 1996.
53. Conry, R. M. Kazaeli, M. B., Saleh, M. N., Ghetie, V., Vitetta, E. S., Liu, T., and LoBuglio, A. F. Phase I trial of an anti-CD19 deglycosylated ricin A chain immunotoxin in non-Hodkgin's lymphoma: effect of an intensive schedule of administration. J. Immunother. Emphas. Tumor Immunol., 18: 231-241, 1995.
54. Wenning, L. A., and Murphy, R. M. Coupled cellular trafficking and diffusional limitations in delivery of immunotoxins to multicell tumor spheroids. Biotechnol. Bioeng., 62: 562-575, 1999.
55. Sung, C., and van Osdol, W. Effects of molecular weight and intracellular processing on tumor penetration of immunotoxins. Proceedings of the Fourth International Symposium on Immunotoxins, Myrtle Beach, p. 107, 1995.
56. Pai, L., FitzGerald, D., Tepper, M., Schacter, B., Spitalny, G., and Pastan, I. Inhibition of antibody response to Pseudomonas exotoxin and an immunotoxin containing Pseudomonas exotoxin by 15-deoxyspergualin in mice. Cancer Res., 50: 7750-7753, 1990.
57. Linsley, P., and Ledbetter, J. The role of CD28 receptor during T cell responses to antigen. Annu. Rev. Immunol., 11: 191-212, 1993.
58. Rybak, S., Hoogenboom, H., Meade, H., and Youle, R. Humanization of immunotoxins. Proc. Natl. Acad. Sci. USA, 89: 3165-3169, 1992.
59. Ehrlich, P. The relationship existing between chemical constitution, distribution and pharmacological action. In: I. F. Himmelweite and H. Dale (eds.). The Collected Papers of Paul Ehrlich, Vol. I., p. 596. London: Pergammon Press, 1956.